Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule Formulations

NCT02258321 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Pharmacokinetic Assessments in Healthy Volunteers

Interventions

DRUG: PPI-668 tablet
DRUG: PPI-668 capsule

Sponsor

Presidio Pharmaceuticals, Inc.